Beta-blockers provide a differential survival benefit in patients with coronary artery disease undergoing contemporary post-percutaneous coronary intervention management

Abstract Beta-adrenergic receptor blockers are used in patients with coronary artery disease (CAD) to reduce the harmful effects of excessive adrenergic activation on the heart. However, there is limited evidence regarding the benefit of beta-blockers in the context of contemporary management follow...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Pil Hyung Lee, Gyung-Min Park, Seungbong Han, Yong-Giun Kim, Jong-Young Lee, Jae-Hyung Roh, Jae-Hwan Lee, Young-Hak Kim, Seung-Whan Lee
Formato:	article
Lenguaje:	EN
Publicado:	Nature Portfolio 2020
Materias:	Medicine R Science Q
Acceso en línea:	https://doaj.org/article/5bd891b9d5694652b995f08a89f433cb
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:5bd891b9d5694652b995f08a89f433cb
record_format	dspace
spelling	oai:doaj.org-article:5bd891b9d5694652b995f08a89f433cb2021-12-02T13:34:09ZBeta-blockers provide a differential survival benefit in patients with coronary artery disease undergoing contemporary post-percutaneous coronary intervention management10.1038/s41598-020-79214-02045-2322https://doaj.org/article/5bd891b9d5694652b995f08a89f433cb2020-12-01T00:00:00Zhttps://doi.org/10.1038/s41598-020-79214-0https://doaj.org/toc/2045-2322Abstract Beta-adrenergic receptor blockers are used in patients with coronary artery disease (CAD) to reduce the harmful effects of excessive adrenergic activation on the heart. However, there is limited evidence regarding the benefit of beta-blockers in the context of contemporary management following percutaneous coronary intervention (PCI). We used the nationwide South Korea National Health Insurance database to identify 87,980 patients with a diagnosis of either acute myocardial infarction (AMI; n = 38,246) or angina pectoris (n = 49,734) who underwent PCI between 2013 and 2017, and survived to be discharged from hospital. Beta-blockers were used in a higher proportion of patients with AMI (80.6%) than those with angina (58.9%). Over a median follow-up of 2.2 years (interquartile range 1.2–3.3 years) with the propensity-score matching analysis, the mortality risk was significantly lower in patients treated with a beta-blocker in the AMI group (HR: 0.78; 95% CI 0.69–0.87; p < 0.001). However, the mortality risk was comparable regardless of beta-blocker use (HR: 1.07; 95% CI 0.98–1.16; p = 0.10) in the angina group. The survival benefit associated with beta-blocker therapy was most significant in the first year after the AMI event.Pil Hyung LeeGyung-Min ParkSeungbong HanYong-Giun KimJong-Young LeeJae-Hyung RohJae-Hwan LeeYoung-Hak KimSeung-Whan LeeNature PortfolioarticleMedicineRScienceQENScientific Reports, Vol 10, Iss 1, Pp 1-9 (2020)
institution	DOAJ
collection	DOAJ
language	EN
topic	Medicine R Science Q
spellingShingle	Medicine R Science Q Pil Hyung Lee Gyung-Min Park Seungbong Han Yong-Giun Kim Jong-Young Lee Jae-Hyung Roh Jae-Hwan Lee Young-Hak Kim Seung-Whan Lee Beta-blockers provide a differential survival benefit in patients with coronary artery disease undergoing contemporary post-percutaneous coronary intervention management
description	Abstract Beta-adrenergic receptor blockers are used in patients with coronary artery disease (CAD) to reduce the harmful effects of excessive adrenergic activation on the heart. However, there is limited evidence regarding the benefit of beta-blockers in the context of contemporary management following percutaneous coronary intervention (PCI). We used the nationwide South Korea National Health Insurance database to identify 87,980 patients with a diagnosis of either acute myocardial infarction (AMI; n = 38,246) or angina pectoris (n = 49,734) who underwent PCI between 2013 and 2017, and survived to be discharged from hospital. Beta-blockers were used in a higher proportion of patients with AMI (80.6%) than those with angina (58.9%). Over a median follow-up of 2.2 years (interquartile range 1.2–3.3 years) with the propensity-score matching analysis, the mortality risk was significantly lower in patients treated with a beta-blocker in the AMI group (HR: 0.78; 95% CI 0.69–0.87; p < 0.001). However, the mortality risk was comparable regardless of beta-blocker use (HR: 1.07; 95% CI 0.98–1.16; p = 0.10) in the angina group. The survival benefit associated with beta-blocker therapy was most significant in the first year after the AMI event.
format	article
author	Pil Hyung Lee Gyung-Min Park Seungbong Han Yong-Giun Kim Jong-Young Lee Jae-Hyung Roh Jae-Hwan Lee Young-Hak Kim Seung-Whan Lee
author_facet	Pil Hyung Lee Gyung-Min Park Seungbong Han Yong-Giun Kim Jong-Young Lee Jae-Hyung Roh Jae-Hwan Lee Young-Hak Kim Seung-Whan Lee
author_sort	Pil Hyung Lee
title	Beta-blockers provide a differential survival benefit in patients with coronary artery disease undergoing contemporary post-percutaneous coronary intervention management
title_short	Beta-blockers provide a differential survival benefit in patients with coronary artery disease undergoing contemporary post-percutaneous coronary intervention management
title_full	Beta-blockers provide a differential survival benefit in patients with coronary artery disease undergoing contemporary post-percutaneous coronary intervention management
title_fullStr	Beta-blockers provide a differential survival benefit in patients with coronary artery disease undergoing contemporary post-percutaneous coronary intervention management
title_full_unstemmed	Beta-blockers provide a differential survival benefit in patients with coronary artery disease undergoing contemporary post-percutaneous coronary intervention management
title_sort	beta-blockers provide a differential survival benefit in patients with coronary artery disease undergoing contemporary post-percutaneous coronary intervention management
publisher	Nature Portfolio
publishDate	2020
url	https://doaj.org/article/5bd891b9d5694652b995f08a89f433cb
work_keys_str_mv	AT pilhyunglee betablockersprovideadifferentialsurvivalbenefitinpatientswithcoronaryarterydiseaseundergoingcontemporarypostpercutaneouscoronaryinterventionmanagement AT gyungminpark betablockersprovideadifferentialsurvivalbenefitinpatientswithcoronaryarterydiseaseundergoingcontemporarypostpercutaneouscoronaryinterventionmanagement AT seungbonghan betablockersprovideadifferentialsurvivalbenefitinpatientswithcoronaryarterydiseaseundergoingcontemporarypostpercutaneouscoronaryinterventionmanagement AT yonggiunkim betablockersprovideadifferentialsurvivalbenefitinpatientswithcoronaryarterydiseaseundergoingcontemporarypostpercutaneouscoronaryinterventionmanagement AT jongyounglee betablockersprovideadifferentialsurvivalbenefitinpatientswithcoronaryarterydiseaseundergoingcontemporarypostpercutaneouscoronaryinterventionmanagement AT jaehyungroh betablockersprovideadifferentialsurvivalbenefitinpatientswithcoronaryarterydiseaseundergoingcontemporarypostpercutaneouscoronaryinterventionmanagement AT jaehwanlee betablockersprovideadifferentialsurvivalbenefitinpatientswithcoronaryarterydiseaseundergoingcontemporarypostpercutaneouscoronaryinterventionmanagement AT younghakkim betablockersprovideadifferentialsurvivalbenefitinpatientswithcoronaryarterydiseaseundergoingcontemporarypostpercutaneouscoronaryinterventionmanagement AT seungwhanlee betablockersprovideadifferentialsurvivalbenefitinpatientswithcoronaryarterydiseaseundergoingcontemporarypostpercutaneouscoronaryinterventionmanagement
_version_	1718392797559521280

Beta-blockers provide a differential survival benefit in patients with coronary artery disease undergoing contemporary post-percutaneous coronary intervention management

Ejemplares similares